SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 39,756.00 |
| Book Value / Share | 19.48 |
| Price / Book | n/a |
| NCAV ($M) | -28,131.00 |
| NCAV / Share | -13.79 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.21 |
| Return on Assets (ROA) | 0.14 |
| Return on Equity (ROE) | 0.29 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.71 |
| Current Ratio | 0.90 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 26,447.00 |
| Assets | 94,334.00 |
| Liabilities | 54,578.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 46,660.00 |
| Operating Income | 12,642.00 |
| Net Income | 14,850.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 14,458.00 |
| Cash from Investing | 5,596.00 |
| Cash from Financing | -14,278.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock Inc. | 6.10 | 6.41 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 238,226 | 1,379,312 | 17.27 | |
| 359,846 | 2,421,300 | 14.86 | |
| 360,438 | 2,472,990 | 14.57 | |
| 768,591 | 3,837,430 | 20.03 | |
| 332,346 | 2,447,775 | 13.58 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABBV – AbbVie Inc. | ABT – Abbott Laboratories |
| ADCT – ADC Therapeutics SA | ANRO – Alto Neuroscience, Inc. |
| ANVS – Annovis Bio, Inc. |
Financial data and stock pages provided by
Fintel.io